论文部分内容阅读
目的研究黄芪注射液联合肝动脉化疗栓塞(Transcatheter Arterial Chemoembolization,TACE)治疗原发性肝癌(中晚期)的临床表现。方法将56例原发性肝癌(中晚期)患者随机分成治疗组和对照组,各28例。治疗组采用黄芪注射液联合TACE的方法治疗;对照组单纯用TACE治疗。于治疗后2、7、21天观察疗效,并随访跟踪生存期。结果术后治疗组病人3个月生存率为92.86%(P<0.05),6个月为67.86%(P<0.01),12个月为32.14%(P<0.05),18个月为14.29%(P<0.05);肝功能ALT水平在术后2天为84.4±12.3 u/L,7天为70.9±11.4 u/L,21天为49.3±8.4u/L(P<0.01);白细胞下降率为21.43%(P<0.05),与对照组相比较均得到有效的改善,同时术后治疗组病人的疗效(P<0.05)、栓塞后综合征出现情况(P<0.01)也得到了明显的改善。结论黄芪注射液联合TACE治疗原发性肝癌,不仅可增加生存率、减轻栓塞后综合征,还可减少术后肝脏损害,防止白细胞下降,提高患者生存质量,值得推广。
Objective To study the clinical manifestations of primary hepatocellular carcinoma (middle and late stage) treated with Astragalus injection and Transcatheter Arterial Chemoembolization (TACE). Methods 56 patients with primary liver cancer (middle and late stage) were randomly divided into treatment group and control group, 28 cases each. Treatment group with Astragalus injection combined with TACE treatment; control group was treated with TACE alone. The effect was observed 2, 7 and 21 days after treatment, and the survival was followed up. Results The 3-month survival rate was 92.86% (P <0.05) in the postoperative treatment group, 67.86% at 6 months (P <0.01), 32.14% at 12 months and 14.29% at 18 months (P <0.05). The level of ALT in liver function was 84.4 ± 12.3 u / L at 2 days after operation, 70.9 ± 11.4 u / L at 7 days and 49.3 ± 8.4 u / L at 21 days (P <0.01) (P <0.05). The effective rate was 21.43% (P <0.05), which was significantly improved compared with the control group. Meanwhile, the curative effect of patients in the postoperative treatment group (P <0.05) and the incidence of post-embolization syndrome (P <0.01) Improvement. Conclusion Astragalus injection combined with TACE treatment of primary liver cancer, not only can increase the survival rate, reduce post-embolization syndrome, but also reduce postoperative liver damage, prevent leukopenia and improve patient quality of life, it is worth promoting.